-transparent.png){kind=logo}
Although superoxide dismutase (SOD) has been reported to promote functional recovery in ischemic spinal cord injury, it presents many difficulties in practical use primarily due to its short half-life in vivo and low tissue affinity. In this study, we investigated the effects of a new type of SOD, a lecithinized superoxide dismutase (PC-SOD), on motor disturbances, spinal cord edema, levels of myeloperoxidase (MPO), and spinal cord blood flow (SCBF) after spinal cord injury (SCI) in rats. PC-SOD is reported to show a delayed plasma disappearance in vivo in rats and has a higher affinity for vascular endothelium cells, neutrophils, and other cells than unmodified SOD. PC-SOD (4000 units/kg), unmodified SOD (4000 units/kg), or vehicle was injected intravenously 30 min after SCI. Four hours after SCI, SOD activities in spinal cord tissue and plasma were significantly higher in the PC-SOD group than in the unmodified SOD group. In the PC-SOD-treated rats, motor function was significantly better than in the other 2 groups of rats. PC-SOD significantly suppressed MPO activity, an indicator of neutrophils infiltration, in the spinal cord, at 4, 8, and 24 h after SCI, and spinal cord edema at 24 h after SCI. Moreover, the decrease of SCBF after SCI was less marked in the PC-SOD group. The present results suggest that lecithinization can improve the drug delivery of SOD to the spinal cord and PC-SOD may be an alternative pharmacological treatment for SCI.
K Nakauchi, and
T Ikata, and
S Katoh, and
Y Hamada, and
K Tsuchiya, and
K Fukuzawa
October 1997,
Journal of neurotrauma,
K Nakauchi, and
T Ikata, and
S Katoh, and
Y Hamada, and
K Tsuchiya, and
K Fukuzawa
January 2001,
Journal of neurotrauma,
K Nakauchi, and
T Ikata, and
S Katoh, and
Y Hamada, and
K Tsuchiya, and
K Fukuzawa
December 2000,
European journal of pharmacology,
K Nakauchi, and
T Ikata, and
S Katoh, and
Y Hamada, and
K Tsuchiya, and
K Fukuzawa
January 2022,
Life sciences,
K Nakauchi, and
T Ikata, and
S Katoh, and
Y Hamada, and
K Tsuchiya, and
K Fukuzawa
September 2011,
The Journal of pharmacology and experimental therapeutics,
K Nakauchi, and
T Ikata, and
S Katoh, and
Y Hamada, and
K Tsuchiya, and
K Fukuzawa
August 2001,
Kidney international,
K Nakauchi, and
T Ikata, and
S Katoh, and
Y Hamada, and
K Tsuchiya, and
K Fukuzawa
September 2002,
Journal of neurotrauma,
K Nakauchi, and
T Ikata, and
S Katoh, and
Y Hamada, and
K Tsuchiya, and
K Fukuzawa
July 2000,
Free radical biology & medicine,
K Nakauchi, and
T Ikata, and
S Katoh, and
Y Hamada, and
K Tsuchiya, and
K Fukuzawa
January 2009,
The Journal of pharmacology and experimental therapeutics,
K Nakauchi, and
T Ikata, and
S Katoh, and
Y Hamada, and
K Tsuchiya, and
K Fukuzawa
January 2006,
Journal of controlled release : official journal of the Controlled Release Society,
